TCM Biotech International Accounts Payable

TCM Biotech International (4169.TWO) currently reports a accounts payable of $43M as of December 2025. That compares with $13M in the prior-year period — up 225.3% year over year. Use the charts on this page to explore TCM Biotech International's accounts payable history and peer comparisons.

TCM Biotech International's accounts payable increased from $13M to $43M — a 225.3% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

TCM Biotech International reported $43M in accounts payable as of December 2025. That compares with $13M in the prior-year period — up 225.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $43M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for TCM Biotech International, and consider following 4169.TWO for alerts when major investors trade the stock.

TCM Biotech International is classified in the Healthcare sector. On accounts payable, it currently shows $43M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4169.TWO with unrelated industries.